Clinical Trial Update: Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating OMS906 in paroxysmal nocturnal hemoglobinuria patients with suboptimal response to ravulizumab reports safety and efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• OMS906 (OMS906)
• Ravulizumab (ravulizumab)

Snippet

Sponsor: Omeros Corporation | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED